European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE
EDITORS IN CHIEF
L. Cecchi (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS
R. Rodrigues Alves (Portugal)
M.B. Bilò (Italy)
 
ASSOCIATE EDITORS
R. Asero (Italy)
M. Branco Ferreira (Portugal)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
D. Villalta (Italy)
S. Voltolini (Italy)

FOUNDERS
F. Bonifazi (Italy)
A. Sabbah (France)
************************* 

Chief Business & Content Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Elisa Grignani
e.grignani@lswr.it
Ph. 0039 (0)2-88184.101

Production Manager
Paolo Ficicchia
p.ficicchia@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

Printing
Rotomail Italia S.p.A.
Strada Rivoltana (SP 14)
12/AB 20060 Vignate (MI), Italy 

EDRA SpA 
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edizioniedra.it
Contents »

Subcutaneous and sublingual allergen-specific immunotherapy: a tale of two routes


C. Incorvaia1, G. Ciprandi gio.cip@libero.it2, M. C. Nizi3, E. Makri1, E. Ridolo3

Show more: Authors information and Publication history

Doi
http://doi.org/10.23822/EurAnnACI.1764-1489.150

Summary
Specific immunotherapy is the only treatment acting on the causes and not only on symptoms of respiratory allergy. It was first introduced as subcutaneous immunotherapy (SCIT) with the aim to induce immunological tolerance to the administered allergen(s). In the 1980s, sublingual immunotherapy (SLIT) was developed, mainly to improve the safety, which was a critical issue at that time. This article reviewed the available literature, including a large number of randomized controlled trials, meta-analyses, and real-life studies as well, on the outcomes of SCIT and SLIT concerning the treatment critical issues of the two routes, that are efficacy, safety, cost-effectiveness, and compliance to treatment. The efficacy of SCIT and SLIT is similar in respiratory allergy, providing, based on the induction of typical changes in the immunologic response, an early control of symptoms that steadily increases during the treatment and its efficacy lasts after the recommended duration of three years. Such results are the reason why SCIT and SLIT have economic advantage over symptomatic drugs.

Key words
Allergen immunotherapy; respiratory allergy; subcutaneous route, sublingual route; efficacy; safety


FULL TEXT